In a second sub study from the Essence-TIMI 73b trial presented at ACC, TG reductions with olezarsen were greater in participants taking fibrates at baseline than in those who were not taking these agents. In the analysis, 309/1,349 trial patients were fibrate users, and these were younger (61 vs 64 years), more often male (65% vs 58%), and had higher TGs (257 mg/dL vs 234 mg/dL), VLDL-C, and apoB than non-users.
Educational partners and supporters
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
